{"id":418506,"date":"2021-01-21T08:03:15","date_gmt":"2021-01-21T13:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=418506"},"modified":"2021-01-21T08:03:15","modified_gmt":"2021-01-21T13:03:15","slug":"eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/","title":{"rendered":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea<\/b><\/p>\n<p><i>&#8211; Starting the Phase I\/II trial in Eunpyeong St. Mary\u2019s Hospital<\/i><\/p>\n<p>SEOUL, South Korea&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.eubiologics.com%2Fen%2Fmain%2F&amp;esheet=52365168&amp;newsitemid=20210121005311&amp;lan=en-US&amp;anchor=EuBiologics&amp;index=1&amp;md5=6a320b18e20412f96cb541648a13ae69\">EuBiologics<\/a> (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I\/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20210121005311\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210121005311\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/4\/EUBIO_PHOTO.jpg\" alt=\"EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I\/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. (Photo: Business Wire)\" \/><\/p>\n<p style=\"font-size:85%\">EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I\/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. (Photo: Business Wire)<\/p>\n<\/div>\n<p>\nThe Phase I trial is designed for 50 healthy adults aged from 19 to 50 years old and will be conducted at \u2018the Catholic University of Korea Eunpyeong St. Mary\u2019s Hospital\u2019 evaluating safety, tolerance and immunogenicity. The Phase II trial will be subsequently carried out for 230 adults aged from 19 to 75 years old in four hospitals located in Seoul metropolitan area in order to evaluate dosage and vaccine immunogenicity.\n<\/p>\n<p>\nEuCorVac-19 under development by EuBiologics is a safe vaccine formulated with the coronavirus spike protein using the recombinant protein technology and with a potent adjuvant, similar to the other virus vaccines already licensed in the world. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals.\n<\/p>\n<p>\nA company official said, \u201cEuCorVac-19 is designed to induce a rapid antibody response, a high level of neutralizing antibody and excellent cellular immune response by combining both SNAP technology of POP Biotechnologies that EuBiologics has invested and EulMT in-licensed from Korea Institute of Science and Technology. EuCorVac-19 has demonstrated superior immune response against SARS-CoV-2 in the animal model, therefore, we expect to see the safety, tolerance and immunogenicity demonstrated in the Phase I\/II trials.\u201d\n<\/p>\n<p>\nEuBiologics plans to consult with the Korean Ministry of Food and Drug Safety in order to progress the Phase III clinical trial later this year based on the interim results of the Phase I\/II trial available no later than June 2021 and receive an emergency use approval of EuCorVac-19, as early as possible. EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210121005311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210121005311\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210121005311\/en\/<\/a><\/span><\/p>\n<p>\nEuBiologics Co., Ltd.<br \/>\n<br \/>Tae Young Jin<br \/>\n<br \/>+82-70-4881-7117<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:yjtae@eubiologics.com\">yjtae@eubiologics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Asia Pacific South Korea<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Other Manufacturing Research Infectious Diseases Hospitals Clinical Trials Manufacturing Biotechnology Pharmaceutical Health Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/3\/EUBIO_PHOTO.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I\/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. (Photo: Business Wire)<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853637\/3\/EUBIOLOGICS_bigger_logo1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea &#8211; Starting the Phase I\/II trial in Eunpyeong St. Mary\u2019s Hospital SEOUL, South Korea&#8211;(BUSINESS WIRE)&#8211;EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I\/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210121005311\/en\/ EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I\/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-418506","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#039;EuCorVac-19&#039; in Korea - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#039;EuCorVac-19&#039; in Korea - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea &#8211; Starting the Phase I\/II trial in Eunpyeong St. Mary\u2019s Hospital SEOUL, South Korea&#8211;(BUSINESS WIRE)&#8211;EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I\/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210121005311\/en\/ EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I\/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with &hellip; Continue reading &quot;EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-21T13:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/4\/EUBIO_PHOTO.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EuBiologics Gets an IND Approval for Phase I\\\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea\",\"datePublished\":\"2021-01-21T13:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/\"},\"wordCount\":600,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210121005311\\\/en\\\/853586\\\/4\\\/EUBIO_PHOTO.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/\",\"name\":\"EuBiologics Gets an IND Approval for Phase I\\\/II Clinical Trial of 'EuCorVac-19' in Korea - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210121005311\\\/en\\\/853586\\\/4\\\/EUBIO_PHOTO.jpg\",\"datePublished\":\"2021-01-21T13:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210121005311\\\/en\\\/853586\\\/4\\\/EUBIO_PHOTO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210121005311\\\/en\\\/853586\\\/4\\\/EUBIO_PHOTO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EuBiologics Gets an IND Approval for Phase I\\\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of 'EuCorVac-19' in Korea - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/","og_locale":"en_US","og_type":"article","og_title":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of 'EuCorVac-19' in Korea - Market Newsdesk","og_description":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea &#8211; Starting the Phase I\/II trial in Eunpyeong St. Mary\u2019s Hospital SEOUL, South Korea&#8211;(BUSINESS WIRE)&#8211;EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I\/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210121005311\/en\/ EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I\/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with &hellip; Continue reading \"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-21T13:03:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/4\/EUBIO_PHOTO.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea","datePublished":"2021-01-21T13:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/"},"wordCount":600,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/4\/EUBIO_PHOTO.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/","name":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of 'EuCorVac-19' in Korea - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/4\/EUBIO_PHOTO.jpg","datePublished":"2021-01-21T13:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/4\/EUBIO_PHOTO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20210121005311\/en\/853586\/4\/EUBIO_PHOTO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eubiologics-gets-an-ind-approval-for-phase-i-ii-clinical-trial-of-eucorvac-19-in-korea\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of &#8216;EuCorVac-19&#8217; in Korea"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/418506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=418506"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/418506\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=418506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=418506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=418506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}